论文部分内容阅读
Estrogen exhibits a broad spectrum of physiologicalfunctions ranging from regulation of the menstrual cycleand reproduction to the modulation of bone density,brainfunction,and cholesterol mobilization.However,estrogenis also associated with pathological complications par-ticularly with the onset of gynaecological malignanciesincluding breast cancer and endometrial cancer;estrogenis now considered to be a classical etiological factor forbreast cancer and endometrial cancer.In the early 1970s,it was reported that there was a 20-35% increase in incidence of endometrial cancer in WesternCaucasian women who had undergone estrogen therapy[1].Subsequently,a variety of clinical and epidemiologi-cal investigations,with support from studies in cell cultureand animal models,have demonstrated the association ofestrogen with the development and/or progression of thedisease.In 2002,the US National Toxicology Programlisted steroidal estrogens as carcinogens for the first time.The report cites data from human epidemiologic studies thatshow an association between estrogen replacement therapyand an increase in the risk of endometrial cancer,as well asa less consistent increase in the risk of breast cancer.
Estrogen exhibits a broad spectrum of physiologicalfunctions ranging from regulation of the menstrual cycle and reproduction to the modulation of bone density, brain function, and cholesterol mobilization. Despite, estrogenis also associated with pathological complications par- ticularly with the onset of gynecological malignanciesincluding breast cancer and endometrial cancer ; estrogenis now considered to be a classical etiological factor forbreast cancer and endometrial cancer. In the early 1970s, it was reported that there was a 20-35% increase in incidence of endometrial cancer in WesternCaucasian women who had undergone estrogen therapy [1]. A variety of clinical and epidemiologi- cal investigations, with support from studies in cell culture and animal models, have demonstrated the association of estrogen with the development and / or progression of the disease. In 2002, the US National Toxicology Program listed steroidal estrogens as carcinogens for the first time. report cites data fr om human epidemiologic studies that show an association between estrogen replacement therapy and an increase in the risk of endometrial cancer, as well as a less consistent increase in the risk of breast cancer.